pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 40 Non-oncology: 28
Oncology: 12
Under Consideration for Negotiation 12 Non-oncology: 6
Oncology: 6
Completed Negotiations 814 With Letter of Intent: 705
Without agreement: 109
Negotiations That Were Not Pursued 109

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Oslya Mantra Pharma Multiple Indications
Bildyos Organon Canada Inc. Multiple Indications
Idenos Apotex Inc. Multiple Indications
Obodence Samsung Bioepis Co., Ltd. Multiple Indications
Osdenza Apotex Inc. Osteoporosis
Symtuza Janssen Inc. HIV-1 Infection
Bilprevda Organon Canada Inc. Multiple Indications
Rystiggo UCB Canada Inc. Generalized myasthenia gravis (gMG)
Imfinzi AstraZeneca Canada Inc. in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment
Pemazyre Incyte Biosciences Canada Corporation For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement.​
Spevigo Boehringer Ingelheim (Canada) Ltd. generalized pustular psoriasis (GPP)

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Fruzaqla Takeda Canada Inc. For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemother
Vemlidy Gilead Sciences Canada Inc. chronic Hepatitis B virus
TheraSphere Y-90 Glass Micropheres Boston Scientific Corporation As selective internal radiation therapy (SIRT) for local tumor control of solitary tumors in patients with intermediate- or advanced-stage hepatocellular carcinoma (HCC), including those with recurrent or unresectable HCC. In addition to HCC
Keytruda Merck Canada Inc. For the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy.
Vabysmo Hoffmann-La Roche Ltd. Retinal vein occlusion
Filra Jamp Pharma Corporation Multiple Indications
Venclexta AbbVie Corporation In combination with Gazyva, for the treatment of patients with previously untreated chronic lymphocytic leukemia
Pexegra Jamp Pharma Corporation Febrile neutropenia in non-myeloid malignancies
Gazyva Hoffmann-La Roche Ltd. In combination with Venclexta, for the treatment of patients with previously untreated chronic lymphocytic leukemia
Kymriah Novartis Pharmaceuticals Canada Inc. Follicular lymphoma (FL), Relapsed or refractory, grade 1, 2 or 3a, in adult patients after two or more lines of systemic therapy
Livmarli Mirum Pharmaceuticals Inc. Alagille syndrome
Myalepta Medison Pharma Canada Inc. Leptin deficiency in lipodystrophy
Padcev Pfizer Canada ULC In combination with pembrolizumab, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC.
Breyanzi Bristol Myers Squibb Canada Inc. Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising from follicular lymphoma, who have refractory di

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Awiqli Novo Nordisk Canada Inc. Diabetes Mellitus, Type 2
Jardiance Boehringer Ingelheim (Canada) Ltd. Adjunct to standard of care therapy for the treatment of chronic heart failure in adults

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Ryaltris Bausch Health, Canada Inc. Seasonal allergic rhinitis